The Framingham Heart Study is a project of Boston University & the National Heart, Lung, & Blood Institute.
The Framingham Heart Study is a project of Boston University & the National Heart, Lung, & Blood Institute.
Research Application Login For Researchers Research Application FAQ Data & Materials Distribution Agreement Review Committees Manuals of Procedures GWAS Pleiotropic Tool AHA Genome Phenome Study

Wi-Cell Policy

Cohort Study Collection Text

Framingham Heart Study (FHS) Cohort

The Framingham Heart Study (FHS) began in 1948 by recruiting an original cohort of 5,209 men and women between the ages of 30-62 years from the town of Framingham, Massachusetts who had not yet developed overt symptoms of cardiovascular disease or suffered a heart attack or stroke. The Offspring Study was initiated in 1971 when the need for establishing a prospective epidemiologic study of young adults was recognized. Please visit the Framingham Heart Study website for additional information.

NHLBI Next Generation Genetic Association Studies (Next Gen) Collection

NHLBI Next Gen – Framingham Heart Study (Dr. Chad Cowan, formerly Harvard Stem Cell Institute)

This collection, from Dr. Chad Cowan (formerly Harvard Stem Cell Institute), was generated to confirm identified variants through differentiation of induced pluripotent stem cells to study cellular pathophysiology.

The Framingham Heart Study has provided knowledge about the epidemiology of hypertensive or arteriosclerotic cardiovascular disease. These cell lines may be useful in studying cardiovascular disease.

Peripheral blood mononuclear cells from 34 Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort participants were reprogrammed into iPSC lines. Upon initial deposit of this collection, 17 participants were homozygous for the major haplotype at the 1p13 locus and 17 participants were homozygous for the minor haplotype at the 1p13 locus. Two clones from each donor were further expanded resulting in a total of 70 iPSC lines. The focus of deriving these cell lines was to differentiate iPSC lines into hepatocytes and adipocytes to investigate the effect of the 1p13 rs12740374 variant on cardiometabolic disease phenotypes via transcriptomics and metabolomics signatures. The age of donors ranges from 51-90 years. To protect donor identity, an age range rather than exact age is provided.

Please see Table S1 from the publication describing this collection of cell lines for additional information on these cell lines including:

Application to and approval by the Framingham Heart Study is necessary to receive these cell lines. You can begin your research application here.

About the Next Generation Genetic Association Studies (Next Gen) Program

These cell lines were created as Next Generation Genetic Association Studies (Next Gen) Program, which was a five-year, $80 million program to investigate functional genetic variation in humans by assessing cellular profiles that are surrogates for disease phenotypes. To achieve this, researchers from multiple institutions across the U.S. were awarded grants to derive iPS cell lines from more than 1,500 individuals representing various conditions as well as healthy controls for use in functional genomic (‘disease in a dish’) research. This extensive panel includes a diverse set of age, gender and ethnic backgrounds, and therefore will be an invaluable tool for evaluations across demographics. Further enhancing the utility of these cell lines are data sets such as phenotyping, GWAS, genome sequencing, gene expression and -omics analyses (e.g., lipidomic, proteomic, methylomic) that will be made available with the cell lines.